Connecticut-based ReNetX Bio, a biotechnology company working to reverse disease and damage for patients suffering from spinal cord injury and other central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204. You may be able to participate in the clinical trial if you are 18-65 years of age and have traumatic cervical SCI that occurred at least one year ago that impairs your ability to use your arms and hands.
Axonal loss is a common, yet unaddressed pathology, in a broad range of chronic and acute diseases of the central and ocular nervous systems. AXER-204 is the first in a new class of therapy designed to remove inhibitory proteins from the CNS environment allowing for axonal regrowth and increased plasticity. These changes harness the body’s ability to regenerate new neural connections through rewiring. “Given the promising results seen in preclinical studies, it is our hope that AXER-204 will become the first therapeutic shown to restore function and reverse damage in spinal cord injury and other CNS diseases,” says ReNetX President and CSO George Maynard, PhD.
The Phase 1 open-label, dose escalation “RESET” trial will evaluate the safety, tolerability, and pharmacokinetics of AXER-204 in patients with chronic spinal cord injury and is expected to enroll approximately 24 patients. You will not be able to participate in this study if you:
• Are pregnant or breastfeeding
• Suffered SCI from a penetrating injury or gunshot
• Require ventilatory assistance
• Have any medical conditions that would increase the risks with undergoing lumbar punctures
For more information about the RESET Study, including contact information for sites that are actively recruiting, CLICK HERE and scroll to the bottom of the page to see the locations recruiting candidates and the contact information.